UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 2, 2012, Pages 221-227

  Haslemo, T ^a   Loryan, I ^b,c   Ueda, N ^d   Mannheimer, B ^b   Bertilsson, L ^d   Ingelman Sundberg, M ^b   Molden, E ^a,e   Eliasson, E ^b  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

10 N GLUCURONIDE; DRUG METABOLITE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A4; LAMOTRIGINE; LEUCINE; OLANZAPINE; UNCLASSIFIED DRUG; VALINE; VALPROIC ACID; BENZODIAZEPINE DERIVATIVE; BILIRUBIN GLUCURONOSIDE GLUCURONOSYLTRANSFERASE; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE; NEUROLEPTIC AGENT;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CELLULAR DISTRIBUTION; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG GLUCURONIDATION; DRUG MONITORING; ENZYME METABOLISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SMOKING; BIPOLAR DISORDER; DRUG EFFECT; GENETICS; LIVER; METABOLIC CLEARANCE RATE; METABOLISM; MULTIVARIATE ANALYSIS; NORWAY; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; FEMALE; GENOTYPE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; LIVER; MALE; METABOLIC CLEARANCE RATE; MULTIVARIATE ANALYSIS; NORWAY; RETROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 84864138748     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.46     Document Type: Article

References (27)

1. Citrome, L. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin. Pharmacother. (2011); published online 17 October 2011.
2. Lieberman, J.A. Et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CAT IE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209-1223 (2005). (Pubitemid 41345943)
3. Hiemke, C. et al. AG NP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44, 195-235 (2011).
4. Melkersson, K.I. & Dahl, M.L. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl.) 170, 157-166 (2003). (Pubitemid 37421527)
5. Perry, P.J. et al. The association of weight gain and olanzapine plasma concentrations. J. Clin. Psychopharmacol. 25, 250-254 (2005). (Pubitemid 40685789)
6. S kogh, E., Reis, M., Dahl, M.L., Lundmark, J. & Bengtsson, F. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther. Drug Monit. 24, 518-526 (2002). (Pubitemid 34857906)
7. Kassahun, K. et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab. Dispos. 25, 81-93 (1997). (Pubitemid 27045138)
8. Ring, B.J. et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J. Pharmacol. Exp. Ther. 276, 658-666 (1996). (Pubitemid 126660505)
9. Linnet, K. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum. Psychopharmacol. 17, 233-238 (2002). (Pubitemid 34823349)
10. Benoit-Biancamano, M.O. et al. A pharmacogenetics study of the human glucuronosyltransferase UGT1A4. Pharmacogenet. Genomics (2009); published online 3 November 2009.
11. G hotbi, R. et al. Carriers of the UGT1A4 142T〉G gene variant are predisposed to reduced olanzapine exposure-an impact similar to male gender or smoking in schizophrenic patients. Eur. J. Clin. Pharmacol. 66, 465-474 (2010).
12. G ulcebi, M.I., Ozkaynakci, A., Goren, M.Z., Aker, R.G., Ozkara, C. & Onat, F.Y. The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res. 95, 1-8 (2011).
13. Laverdie, I., Caron, P., Harvey, M., Lesque, I. & Guillemette, C. In vitro investigation of human UDP-glucuronosyltransferase isoforms responsible for tacrolimus glucuronidation: predominant contribution of UGT1A4. Drug Metab. Dispos. 39, 1127-1130 (2011).
14. S un, D., Chen, G., Dellinger, R.W., Duncan, K., Fang, J.L. & Lazarus, P. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res. 8, R50 (2006).
15. Qian, M.R. & Zeng, S. Biosynthesis of imipramine glucuronide and characterization of imipramine glucuronidation catalyzed by recombinant UGT1A4. Acta Pharmacol. Sin. 27, 623-628 (2006).
16. Mori, A., Maruo, Y., Iwai, M., Sato, H. & Takeuchi, Y. UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab. Dispos. 33, 672-675 (2005). (Pubitemid 40593882)
17. Erickson-Ridout, K.K., Zhu, J. & Lazarus, P. Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. Pharmacogenet. Genomics 21, 539-551 (2011).
18. Kerdpin, O., Mackenzie, P.I., Bowalgaha, K., Finel, M. & Miners, J.O. Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10. Drug Metab. Dispos. 37, 1948-1955 (2009).
19. Magdalou, J., Fournel-Gigleux, S. & Ouzzine, M. Insights on membrane topology and structure/function of UDP-glucuronosyltransferases. Drug Metab. Rev. 42, 159-166 (2010).
20. Weiss, U., Marksteiner, J., Kemmler, G., Saria, A. & Aichhorn, W. Effects of age and sex on olanzapine plasma concentrations. J. Clin. Psychopharmacol. 25, 570-574 (2005). (Pubitemid 41669052)
21. Weintraub, D., Buchsbaum, R., Resor, S.R. Jr & Hirsch, L.J. Effect of antiepileptic drug comedication on lamotrigine clearance. Arch. Neurol. 62, 1432-1436 (2005). (Pubitemid 41352061)
22. Spina, E. et al. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. Ther. Drug Monit. 31, 758-763 (2009).
23. G hotbi, R. et al. Carriers of the UGT1A4 142T〉G gene variant are predisposed to reduced olanzapine exposure-an impact similar to male gender or smoking in schizophrenic patients. Eur. J. Clin. Pharmacol. 66, 465-474 (2010).
24. Ren, Q., Murphy, S.E., Zheng, Z. & Lazarus, P. O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab. Dispos. 28, 1352-1360 (2000).
25. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254 (1976).
26. Mkrtchian, S., Fang, C., Hellman, U. & Ingelman-Sundberg, M. A stress-inducible rat liver endoplasmic reticulum protein, ERp29. Eur. J. Biochem. 251, 304-313 (1998). (Pubitemid 28080927)
27. Linnet, K. & Olesen, O.V. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication. Ther. Drug Monit. 24, 512-517 (2002). (Pubitemid 34857905)